Scott Ferguson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Scott Ferguson has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Ralph Weissleder
Massachusetts General Hospital
5 shared publications - Jonathan C. T. Carlson
Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, USA
4 shared publications - Katherine S. Yang
Center for Systems Biology Massachusetts General Hospital Harvard Medial School 185 Cambridge Street, CPZN 5206 02114 Boston MA USA
3 shared publications - Andrew Scott Liss
Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, USA
2 shared publications - Christian Landeros
Massachusetts General Hospital, Boston, MA
2 shared publications - Hakho Lee
Center for Systems Biology, Massachusetts General Hospital, Boston, MA, 02114, USA; Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA
2 shared publications
Latest Publications
- 24 May 2022
- Published by Elsevier in Trends in Molecular Medicine
- Vol. 28 (8) , 681-692
Single extracellular vesicle analysis for early cancer detection
- 24 May 2022
- Published by Elsevier in Trends in Molecular Medicine
- Vol. 28 (8) , 681-692
Single extracellular vesicle analysis for early cancer detection
- Open Access
- 22 April 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (16) , eabm3453
Single-EV analysis (sEVA) of mutated proteins allows detection of stage 1 pancreatic cancer
Tumor cell–derived extracellular vesicles (EVs) are being explored as circulating biomarkers, but it is unclear whether bulk measurements will allow early cancer detection. We hypothesized that a single-EV analysis (sEVA) technique could potentially improve diagnostic accuracy. Using pancreatic cancer (PDAC), we analyzed the composition of putative cancer markers in 11 model lines. In parental PDAC cells positive for KRAS mut and/or P53 mut proteins, only ~40% of EVs were also positive. In a blinded study involving 16 patients with surgically proven stage 1 PDAC, KRAS mut and P53 mut protein was detectable at much lower levels, generally in 3 tumor volume, below clinical imaging capabilities. These findings establish the potential for sEVA for early cancer detection.
- 22 April 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (16) , eabm3453
Open AccessSingle-EV analysis (sEVA) of mutated proteins allows detection of stage 1 pancreatic cancer
Tumor cell–derived extracellular vesicles (EVs) are being explored as circulating biomarkers, but it is unclear whether bulk measurements will allow early cancer detection. We hypothesized that a single-EV analysis (sEVA) technique could potentially improve diagnostic accuracy. Using pancreatic cancer (PDAC), we analyzed the composition of putative cancer markers in 11 model lines. In parental PDAC cells positive for KRAS mut and/or P53 mut proteins, only ~40% of EVs were also positive. In a blinded study involving 16 patients with surgically proven stage 1 PDAC, KRAS mut and P53 mut protein was detectable at much lower levels, generally in 3 tumor volume, below clinical imaging capabilities. These findings establish the potential for sEVA for early cancer detection.
- 1 January 2022
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 10 (1_Suppleme) , P056
Abstract P056: Rapid serial immunoprofiling of the tumor immune microenvironment by fine needle sampling
As the field of cancer immunotherapy brings forth novel and combinatorial agents, there is increasing effort to discover and integrate predictive and/or prognostic biomarkers into treatment algorithms in order to optimize cancer care. While tissue-based methods can elucidate tumor-immune cell compositions at a single time point, serial assessment of the tumor immune microenvironment (TME) can provide unique insight into how various therapies may modulate target tumor and/or immune cell populations over time. We propose that single-cell sampling via fine needle aspirates (FNA) can facilitate such analyses with a favorable risk-benefit profile. Thus, we developed and optimized a multiplexed bioorthogonal approach (FAST-FNA) which has been coupled with a deep learning algorithm that allows for comprehensive cellular analyses of FNA samples. We demonstrate that the FAST-FNA assay reproducibly captures the TME profile as compared to standard labor-intensive flow cytometry and immunohistochemical assays, and, furthermore, allows for time course analysis of the evolving TME in mouse and human cancers in vivo. The translational significance of the FNA-based technology is highlighted in the ability to rapidly assess PD-L1 expression within the TME and is further extended through the serial quantitation of both tumor and immune cell markers in cancer patients treated with immunotherapy. Collectively, these data indicate that FAST-FNA can serve as a robust and versatile clinical tool to monitor the evolving TME and has the potential to provide early insight into treatment response. Citation Format: Juhyun Oh, Jonathan C. T. Carlson, Christian Landeros, Hakho Lee, Scott Ferguson, William C. Faquin, John R. Clark, Mikael J. Pittet, Sara I. Pai, Ralph Weissleder. Rapid serial immunoprofiling of the tumor immune microenvironment by fine needle sampling [abstract]. In: Abstracts: AACR Virtual Special Conference: Tumor Immunology and Immunotherapy; 2021 Oct 5-6. Philadelphia (PA): AACR; Cancer Immunol Res 2022;10(1 Suppl):Abstract nr P056.
- 1 January 2022
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 10 (1_Suppleme) , P056
Abstract P056: Rapid serial immunoprofiling of the tumor immune microenvironment by fine needle sampling
As the field of cancer immunotherapy brings forth novel and combinatorial agents, there is increasing effort to discover and integrate predictive and/or prognostic biomarkers into treatment algorithms in order to optimize cancer care. While tissue-based methods can elucidate tumor-immune cell compositions at a single time point, serial assessment of the tumor immune microenvironment (TME) can provide unique insight into how various therapies may modulate target tumor and/or immune cell populations over time. We propose that single-cell sampling via fine needle aspirates (FNA) can facilitate such analyses with a favorable risk-benefit profile. Thus, we developed and optimized a multiplexed bioorthogonal approach (FAST-FNA) which has been coupled with a deep learning algorithm that allows for comprehensive cellular analyses of FNA samples. We demonstrate that the FAST-FNA assay reproducibly captures the TME profile as compared to standard labor-intensive flow cytometry and immunohistochemical assays, and, furthermore, allows for time course analysis of the evolving TME in mouse and human cancers in vivo. The translational significance of the FNA-based technology is highlighted in the ability to rapidly assess PD-L1 expression within the TME and is further extended through the serial quantitation of both tumor and immune cell markers in cancer patients treated with immunotherapy. Collectively, these data indicate that FAST-FNA can serve as a robust and versatile clinical tool to monitor the evolving TME and has the potential to provide early insight into treatment response. Citation Format: Juhyun Oh, Jonathan C. T. Carlson, Christian Landeros, Hakho Lee, Scott Ferguson, William C. Faquin, John R. Clark, Mikael J. Pittet, Sara I. Pai, Ralph Weissleder. Rapid serial immunoprofiling of the tumor immune microenvironment by fine needle sampling [abstract]. In: Abstracts: AACR Virtual Special Conference: Tumor Immunology and Immunotherapy; 2021 Oct 5-6. Philadelphia (PA): AACR; Cancer Immunol Res 2022;10(1 Suppl):Abstract nr P056.
- Open Access
Single EV analysis (sEVA) of mutated proteins allows detection of stage 1 pancreatic cancer
Tumor cell derived extracellular vesicles (EV) are being explored as circulating biomarkers for cancer detection. Up to now however, clinical results have been mixed for a number of reasons including the predominant use of bulk measurements, the inability to differentiate tumor from host cell derived vesicles, the general absence of uniquely identifying biomarkers and the unknown frequency of stochastically distributed biomarkers into single circulating vesicles. We hypothesized that a single EV analysis (sEVA) technique could potentially improve diagnostic accuracy necessary to detect early cancers but the actual biomarker frequency and practical detection limits are currently unknown. Using pancreatic cancer, we carefully analyzed the composition of putative cancer markers in 11 established and new patient derived models. In parental PDAC cells positive for KRAS mut and/or P53 mut proteins only ∼40% of EVs were also positive (range: 30-64%). This rate of positivity increased to 57% when additional PDAC biomarkers were considered (MUC1, EGFR, ⍺FG-P4OH) in cell lines. In a blinded study involving 16 patients with surgically proven stage 1 PDAC, KRAS mut and P53 mut protein was detectable at much lower levels, generally in < 0.1% of vesicles. With the analytical capabilities of sEVA however, 15 of the 16 patients with stage 1 PDAC expressed low levels of biomarker positive EV. Using a modeling approach, we estimate that the current PDAC detection limit is at ∼0.1 cm 3 tumor volume, below clinical imaging capabilities. These findings establish the potential for single-EV analysis for early cancer detection.
Open AccessSingle EV analysis (sEVA) of mutated proteins allows detection of stage 1 pancreatic cancer
Tumor cell derived extracellular vesicles (EV) are being explored as circulating biomarkers for cancer detection. Up to now however, clinical results have been mixed for a number of reasons including the predominant use of bulk measurements, the inability to differentiate tumor from host cell derived vesicles, the general absence of uniquely identifying biomarkers and the unknown frequency of stochastically distributed biomarkers into single circulating vesicles. We hypothesized that a single EV analysis (sEVA) technique could potentially improve diagnostic accuracy necessary to detect early cancers but the actual biomarker frequency and practical detection limits are currently unknown. Using pancreatic cancer, we carefully analyzed the composition of putative cancer markers in 11 established and new patient derived models. In parental PDAC cells positive for KRAS mut and/or P53 mut proteins only ∼40% of EVs were also positive (range: 30-64%). This rate of positivity increased to 57% when additional PDAC biomarkers were considered (MUC1, EGFR, ⍺FG-P4OH) in cell lines. In a blinded study involving 16 patients with surgically proven stage 1 PDAC, KRAS mut and P53 mut protein was detectable at much lower levels, generally in < 0.1% of vesicles. With the analytical capabilities of sEVA however, 15 of the 16 patients with stage 1 PDAC expressed low levels of biomarker positive EV. Using a modeling approach, we estimate that the current PDAC detection limit is at ∼0.1 cm 3 tumor volume, below clinical imaging capabilities. These findings establish the potential for single-EV analysis for early cancer detection.
- Open Access
- 7 July 2021
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 27 (17) , 4781-4793
Rapid Serial Immunoprofiling of the Tumor Immune Microenvironment by Fine Needle Sampling
Purpose: There is increasing effort to discover and integrate predictive and/or prognostic biomarkers into treatment algorithms. While tissue-based methods can reveal tumor–immune cell compositions at a single time point, we propose that single-cell sampling via fine needle aspiration (FNA) can facilitate serial assessment of the tumor immune microenvironment (TME) with a favorable risk–benefit profile.Experimental Design: Primary antibodies directed against 20 murine and 25 human markers of interest were chemically modified via a custom linker–bio-orthogonal quencher (FAST) probe. A FAST-FNA cyclic imaging and analysis pipeline were developed to derive quantitative response scores. Single cells were harvested via FNA and characterized phenotypically and functionally both in preclinical and human samples using the newly developed FAST-FNA assay.Results: FAST-FNA samples analyzed manually versus the newly developed deep learning–assisted pipeline gave highly concordant results. Subsequently, an agreement analysis showed that FAST and flow cytometry of surgically resected tumors were positively correlated with an R2 = 0.97 in preclinical samples and an R2 = 0.86 in human samples with the detection of the relevant tumor and immune biomarkers of interest. Finally, the feasibility of applying this minimally invasive approach to analyze the TME during immunotherapy was assessed in patients with cancer revealing local antitumor immune programs.Conclusions: The FAST-FNA is an innovative technology that combines bio-orthogonal chemistry coupled with a computational analysis pipeline for the comprehensive profiling of single cells obtained through FNA. This is the first demonstration that the complex and rapidly evolving TME during treatment can be accurately and serially measured by simple FNA.
- 7 July 2021
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 27 (17) , 4781-4793
Open AccessRapid Serial Immunoprofiling of the Tumor Immune Microenvironment by Fine Needle Sampling
Purpose: There is increasing effort to discover and integrate predictive and/or prognostic biomarkers into treatment algorithms. While tissue-based methods can reveal tumor–immune cell compositions at a single time point, we propose that single-cell sampling via fine needle aspiration (FNA) can facilitate serial assessment of the tumor immune microenvironment (TME) with a favorable risk–benefit profile.Experimental Design: Primary antibodies directed against 20 murine and 25 human markers of interest were chemically modified via a custom linker–bio-orthogonal quencher (FAST) probe. A FAST-FNA cyclic imaging and analysis pipeline were developed to derive quantitative response scores. Single cells were harvested via FNA and characterized phenotypically and functionally both in preclinical and human samples using the newly developed FAST-FNA assay.Results: FAST-FNA samples analyzed manually versus the newly developed deep learning–assisted pipeline gave highly concordant results. Subsequently, an agreement analysis showed that FAST and flow cytometry of surgically resected tumors were positively correlated with an R2 = 0.97 in preclinical samples and an R2 = 0.86 in human samples with the detection of the relevant tumor and immune biomarkers of interest. Finally, the feasibility of applying this minimally invasive approach to analyze the TME during immunotherapy was assessed in patients with cancer revealing local antitumor immune programs.Conclusions: The FAST-FNA is an innovative technology that combines bio-orthogonal chemistry coupled with a computational analysis pipeline for the comprehensive profiling of single cells obtained through FNA. This is the first demonstration that the complex and rapidly evolving TME during treatment can be accurately and serially measured by simple FNA.
- 1 April 2016
- Published by Elsevier in Journal of Controlled Release
- Vol. 228, 179-190
Exosomes as therapeutics: The implications of molecular composition and exosomal heterogeneity
- 1 April 2016
- Published by Elsevier in Journal of Controlled Release
- Vol. 228, 179-190
Exosomes as therapeutics: The implications of molecular composition and exosomal heterogeneity